Proteomic analysis for the anti-apoptotic effects of cystamine on apoptosis-prone macrophage

Journal of Cellular Biochemistry

Volumn 110, Issue 3, 2010, Pages 660-670

  Kao, Shao Hsuan ^a,b   Hsu, Tsai Ching ^a,b   Yu, Jau Song ^c   Chen, Jeng Ting ^c   Li, Sin Lun ^a   Lai, Wen Xian ^a   Tzang, Bor Show ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Apoptosis prone macrophages; Caspase; Cystamine; ERK; Lupus prone mice

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CYSTAMINE; GLUTATHIONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATE BUFFERED SALINE; PROTEIN BAX; PROTEIN BCL 2;

AMINO ACID SEQUENCE; ANALYTICAL EQUIPMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTI APOPTOSIS ACTIVITY; APOPTOSIS; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG INHIBITION; FEMALE; MACROPHAGE; MITOCHONDRION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PEPTIDE MASS FINGERPRINTING; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ANIMALS; APOPTOSIS; CYSTAMINE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; IMMUNOBLOTTING; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED NZB; PEPTIDE MAPPING; PROTEOMICS;

MUS;

EID: 77952696759     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22577     Document Type: Article

References (56)

1. Aeschlimann D, Wetterwald A, Fleisch H, Paulsson M. 1993. Expression of tissue transglutaminase in skeletal tissues correlates with events of terminal differentiation of chondrocytes. J Cell Biol 120:1461-1470. (Pubitemid 23081692)
2. Aeschlimann D, Kaupp O, Paulsson M. 1995. Transglutaminase-catalyzed matrix cross-linking in differentiating cartilage: Identification of osteonectin as a major glutaminyl substrate. J Cell Biol 129:881-892.
3. Berruyer C,Martin FM, Castellano R,Macone A,Malergue F, Garrido-Urbani S, Millet V, Imbert J, Dupre S, Pitari G, Naquet P, Galland F. 2004. Vanin-1-/- mice exhibit a glutathione-mediated tissue resistance to oxidative stress. Mol Cell Biol 24:7214-7224. (Pubitemid 39014447)
4. Boraschi D, Ghezzi P, Salmona M, Tagliabue A. 1982. IFN-beta-induced reduction of superoxide anion generation by macrophages. Immunology 45: 621-628. (Pubitemid 12132269)
5. Bungay PJ, Owen RA, Coutts IC, Griffin M. 1986. A role for transglutaminase in glucose-stimulated insulin release from the pancreatic beta-cell. Biochem J 235:269-278. (Pubitemid 16042001)
6. Cho DH, Hong YM, Lee HJ, Woo HN, Pyo JO, Mak TW, Jung YK. 2004. Induced inhibition of ischemic/hypoxic injury by APIP, a novel Apaf-1-interacting protein. J Biol Chem 279:39942-39950.
7. Chu F, Koomen JM, Kobayashi R, O'Brian CA. 2005. Identification of an inactivating cysteine switch in protein kinase Cepsilon, a rational target for the design of protein kinase Cepsilon-inhibitory cancer therapeutics. Cancer Res 65:10478-10485. (Pubitemid 41743743)
8. Cohen PL. 2006. Apoptotic cell death and lupus. Springer Semin Immunopathol 28:145-152.
9. Cooke MS, Mistry N, Wood C, Herbert KE, Lunec J. 1997. Immunogenicity of DNA damaged by reactive oxygen species-Implications for anti-DNA antibodies in lupus. Free Radic Biol Med 22:151-159. (Pubitemid 26399320)
10. Dardik R, Inbal A. 2006. Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): Proposed mechanism for modulation of endothelial cell response to VEGF. Exp Cell Res 312:2973-2982. (Pubitemid 44292656)
11. Davies PJ, Davies DR, Levitzki A, Maxfield FR, Milhaud P, Willingham MC, Pastan IH. 1980. Transglutaminase is essential in receptor-mediated endocytosis of alpha 2-macroglobulin and polypeptide hormones. Nature 283: 162-167. (Pubitemid 10171126)
12. Denman AM, Denman EJ, Holborow EJ. 1967. Suppression of Coombs-positive haemolytic anaemia in NZB mice by antilymphocyte globulin. Lancet 1:1084-1086.
13. Di Leandro L, Maras B, Schinina ME, Dupre S, Koutris I, Martin FM, Naquet P, Galland F, Pitari G. 2008. Cystamine restores GSTA3 levels in Vanin-1 null mice. Free Radic Biol Med 44:1088-1096.
14. Falasca L, Iadevaia V, Ciccosanti F, Melino G, Serafino A, Piacentini M. 2005. Transglutaminase type II is a key element in the regulation of the anti-inflammatory response elicited by apoptotic cell engulfment. J Immunol 174:7330-7340. (Pubitemid 40705703)
15. Fesus L, Thomazy V, Falus A. 1987. Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett 224:104-108. (Pubitemid 17159992)
16. Hengartner MO. 2000. The biochemistry of apoptosis. Nature 407:770-776.
17. Holborow EJ, Denman AM. 1967. Autoimmune disease in inbred mice. Clin Exp Immunol 2(Suppl.):761-767.
18. Hsu TC, Chiang SY, Huang CY, Tsay GJ, Yang CW, Huang CN, Tzang BS. 2007. Beneficial effects of treatment with transglutaminase inhibitor cystamine on macrophage response in NZB/W F1 mice. Exp Biol Med (Maywood) 232:195-203.
19. Jeon JH, Lee HJ, Jang GY, Kim CW, Shim DM, Cho SY, Yeo EJ, Park SC, Kim IG. 2004. Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine. Exp Mol Med 36:576-581.
20. Johnson TS, Knight CR, el-Alaoui S, Mian S, Rees RC, Gentile V, Davies PJ, Griffin M. 1994. Transfection of tissue transglutaminase into a highly malignant hamster fibrosarcoma leads to a reduced incidence of primary tumour growth. Oncogene 9:2935-2942.
21. Kang TY, El-Sohemy A, Comelis MC, Eny KM, Bae SC. 2005. Glutathione S-transferase genotype and risk of systemic lupus erythematosus in Koreans. Lupus 14:381-384. (Pubitemid 40756447)
22. Kanno T, Sato EE, Muranaka S, Fujita H, Fujiwara T, Utsumi T, Inoue M, Utsumi K. 2004. Oxidative stress underlies the mechanism for Ca(2+)-induced permeability transition of mitochondria. Free Radic Res 38:27-35. (Pubitemid 38128512)
23. Kao SH, Wong HK, Chiang CY, Chen HM. 2008. Evaluating the compatibility of three colorimetric protein assays for two-dimensional electrophoresis experiments. Proteomics 8:2178-2184.
24. Kaplan MJ. 2004. Apoptosis in systemic lupus erythematosus. Clin Immunol 112:210-218.
25. Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, Steinman L. 2002. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8:143-149. (Pubitemid 34155125)
26. Kiama SG, Cochand L, Karlsson L, Nicod LP, Gehr P. 2001. Evaluation of phagocytic activity in human monocyte-derived dendritic cells. J Aerosol Med 14:289-299. (Pubitemid 32802031)
27. Kimmelman AC, Osada M, Chan AM. 2000. R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells. Oncogene 19:2014-2022. (Pubitemid 30229414)
28. Lesort M, Lee M, Tucholski J, Johnson GV. 2003. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 278:3825-3830. (Pubitemid 36801110)
29. Martin F, Malergue F, Pitari G, Philippe JM, Philips S, Chabret C, Granjeaud S, Mattei MG, Mungall AJ, Naquet P, Galland F. 2001. Vanin genes are clustered (human 6q22-24 and mouse 10A2B1) and encode isoforms of pantetheinase ectoenzymes. Immunogenetics 53:296-306. (Pubitemid 32678764)
30. Moritz RL, Eddes JS, Reid GE, Simpson RJ. 1996. S-Pyridylethylation of intact polyacrylamide gels and in situ digestion of electrophoretically separated proteins: A rapid mass spectrometric method for identifying cysteine-containing peptides. Electrophoresis 17:907-917.
31. Mortz E, Krogh TN, Vorum H, Gorg A. 2001. Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ionization-time of flight analysis. Proteomics 1:1359-1363. (Pubitemid 33587891)
32. Mühlradt PF, Frisch M. 1994. Purification and partial biochemical characterization of a Mycoplasma fermentans-derived substance that activates macrophages to release nitric oxide, tumor necrosis factor, and interleukin-6. Infect Immun 62:3801-3807. (Pubitemid 24264323)
33. Munoz LE, Gaipl US, Franz S, Sheriff A, Voll RE, Kalden JR, Herrmann M. 2005. SLE-a disease of clearance deficiency? Rheumatology (Oxford) 44: 1101-1107.
34. Ni H, Wang XS, Diener K, Yao Z. 1998. MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated protein kinase, is a substrate of the extracellular-regulated kinase (ERK) and p38 kinase. Biochem Biophys Res Commun 243:492-496. (Pubitemid 28414052)
35. O'Brian CA, Chu F. 2005. Post-translational disulfide modifications in cell signaling-Role of inter-protein, intra-protein, S-glutathionyl, and S-cysteaminyl disulfide modifications in signal transmission. Free Radic Res 39:471-480. (Pubitemid 40711879)
36. Okado-Matsumoto A, Fridovich I. 2001. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu, Zn-SOD in mitochondria. J Biol Chem 276:38388-38393. (Pubitemid 37371188)
37. Pillai A, Veeranan-Karmegam R, Dhandapani KM, Mahadik SP. 2008. Cystamine prevents haloperidol-induced decrease of BDNF/TrkB signaling in mouse frontal cortex. J Neurochem 107:941-951.
38. Pitidhammabhorn D, Kantachuvesiri S, Totemchokchyakarn K, Kitiyanant Y, Ubol S. 2006. Partial construction of apoptotic pathway in PBMC obtained from active SLE patients and the significance of plasma TNF-alpha on this pathway. Clin Rheumatol 25:705-714. (Pubitemid 44111315)
39. Quilliam LA, Castro AF, Rogers-Graham KS, Martin CB, Der CJ, Bi C. 1999. M-Ras/ R-Ras3, a transforming ras protein regulated by Sos1, GRF1, and p120 Ras GTPase-activating protein, interacts with the putative Ras effector AF6. J Biol Chem 274:23850-23857. (Pubitemid 129528424)
40. Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS. 2003. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48:2888-2897. (Pubitemid 37280618)
41. Revesz L, Modig H. 1965. Cysteamine-induced increase of cellular glutathione-level: A new hypothesis of the radioprotective mechanism. Nature 207:430-431.
42. Rovere P, Sabbadini MG, Fazzini F, Bondanza A, Zimmermann VS, Rugarli C, Manfredi AA. 2000. Remnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity. Arthritis Rheum 43:1663-1672.
43. Russell PJ, Cahill J, Cameron F, Hume D. 1985. Studies of peritoneal macrophage function in murine systemic lupus erythematosus. 2. Nature of elevated resident peritoneal cells in NZB and (NZB x NZW)F1 mice. J Leukoc Biol 38:241-254. (Pubitemid 15243427)
44. Seelig GF, Meister A. 1984. Gamma-glutamylcysteine synthetase. Interactions of an essential sulfhydryl group. J Biol Chem 259:3534-3538. (Pubitemid 14170081)
45. Shaul YD, Seger R. 2007. The MEK/ERK cascade: From signaling specificity to diverse functions. Biochim Biophys Acta 1773:1213-1226. (Pubitemid 47125968)
46. Simon HU, Haj-Yehia A, Levi-Schaffer F. 2000. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5:415-418. (Pubitemid 32162623)
47. Skrede S, Christophersen BO. 1966. Effects of cystamine and cysteamine on the peroxidation of lipids and the release of proteins from mitochondria. Biochem J 101:37-41.
48. Stack EC, Ferro JL, Kim J, Del Signore SJ, Goodrich S, Matson S, Hunt BB, Cormier K, Smith K, Matson WR, Ryu H, Ferrante RJ. 2008. Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. Biochim Biophys Acta 1782:151-162.
49. Suzuki T. 1991. Signal transduction mechanisms through Fc gamma receptors on the mouse macrophage surface. FASEB J 5:187-193. (Pubitemid 21892878)
50. Szondy Z, Sarang Z, Molnar P, Nemeth T, Piacentini M, Mastroberardino PG, Falasca L, Aeschlimann D, Kovacs J, Kiss I, Szegezdi E, Lakos G, Rajnavolgyi E, Birckbichler PJ, Melino G, Fesus L. 2003. Transglutaminase 2-/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. Proc Natl Acad Sci USA 100:7812-7817. (Pubitemid 36760052)
51. Vaarala O. 2000. Antibodies to oxidised LDL. Lupus 9:202-205.
52. Vincent AM, Brownlee M, Russell JW. 2002. Oxidative stress and programmed cell death in diabetic neuropathy. Ann NY Acad Sci 959:368-383. (Pubitemid 34457577)
53. Wang X, Li N, Liu B, Sun H, Chen T, Li H, Qiu J, Zhang L, Wan T, Cao X. 2004. A novel human phosphatidylethanolamine-binding protein resists tumor necrosis factor alpha-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization. J Biol Chem 279:45855-45864. (Pubitemid 39491578)
54. Waszczykowska E, Robak E, Wozniacka A, Narbutt J, Torzecka JD, Sysa-Jedrzejowska A. 1999. Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation. Mediators Inflamm 8:93-100. (Pubitemid 29243183)
55. Williams JM, Colman R, Brookes CJ, Savage CO, Harper L. 2005. Anti-endothelial cell antibodies from lupus patients bind to apoptotic endothelial cells promoting macrophage phagocytosis but do not induce apoptosis. Rheumatology (Oxford) 44:879-884. (Pubitemid 41511182)
56. Wu X, Molinaro C, Johnson N, Casiano CA. 2001. Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: Implications for systemic autoimmunity. Arthritis Rheum 44:2642-2652. (Pubitemid 33049342)